Mode
Text Size
Log in / Sign up

Conservative fluid management shows no difference in tissue perfusion or kidney injury in critically ill adultsLess Fluid in ICU: New Data Shows It Is Safe

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider that conservative fluid management did not worsen perfusion or kidney injury in critically ill adults, but imprecision limits conclusions.

This secondary analysis of the RADAR-2 trial enrolled critically ill adults in ICUs to compare conservative fluid management with active deresuscitation against usual care. The study followed patients for 28 days, assessing tissue hypoperfusion, acute kidney injury, and vascular injury biomarkers.

Whole blood lactate levels were similar between groups at all timepoints. AKIRisk scores and urinary cystatin-C levels showed no statistically detectable between-group differences. Plasma vascular injury biomarkers (hyaluronan, syndecan-1, angiopoietin-2) also had no statistically detectable differences at any timepoint.

High baseline hyaluronan, syndecan-1, and NT-proBNP >2500 pg/mL were independently associated with increased 28-day mortality. The adjusted odds ratios were 5.75 (95% CI 1.94-17.02) for hyaluronan (p=0.002), 8.82 (95% CI 2.67-29.15) for syndecan-1 (p<0.001), and 21.48 (95% CI 3.57-129.41) for NT-proBNP >2500 pg/mL (p<0.001).

Safety data, including adverse events and discontinuations, were not reported. Key limitations include a modest sample size and resultant imprecision, meaning clinically important effects cannot be excluded. Conservative fluid management was not associated with worsening perfusion or kidney injury, but causation for biomarker-mortality links is not established.

Why Fluid Balance Matters

Imagine being in the hospital, hooked up to machines. The doctor says, "We need to take some fluid out." It sounds scary to lose water when you are already weak. Many people worry that less fluid could make things worse.

Too much water in the body can cause swelling. It makes it hard for organs to work properly. Doctors often give fluids to keep blood pressure up. But giving too much can hurt the lungs and heart. Finding the right balance is a daily challenge for staff.

The Risk of Too Much Water

For years, the rule was to give more fluids. But this study asks if less is better. They wanted to see if taking fluids out causes harm. This changes how doctors think about sick patients. It challenges the old habits of the past.

The Shift in Thinking

Think of your blood vessels like a garden hose. If you pump too much water in, the hose might burst. This study checked if the lining of the vessels stayed safe. They looked for signs of damage in the walls. The body needs a steady flow to stay healthy.

How the Body Reacts

Researchers looked at patients in the intensive care unit. They compared two groups: one got less fluid. The other group got usual care from the doctors. They watched for kidney issues and blood flow problems. This was a careful comparison of two different methods.

What the Study Tested

The group with less fluid did just as well. Their kidneys stayed healthy throughout the treatment. Their blood flow remained normal without any issues. Some markers showed higher risk for death in sick people. High levels of certain signs predicted worse outcomes.

The Surprising Results

But there is a catch to this news. This doesn’t mean this treatment is available yet. Experts see this as a step toward better care. It suggests doctors have more options to manage sick patients. It is a piece of the puzzle, not the whole picture.

What This Means Now

If you have a loved one in the ICU, ask about fluid plans. Do not change anything without a doctor's advice. Talk to your medical team about the best path forward. They know your specific situation best. Every patient is different and needs unique care.

The group of patients was small for this study. This makes the results less certain for everyone. We need more data to be sure about safety. Early results often need more testing before trust. Small groups can hide important details about risk.

The Study Limits

More trials will happen to confirm these findings. Approval takes time to ensure safety for everyone. Research moves slowly to protect patient health. Stay tuned for updates on this important work. Science takes time to build a strong foundation.

Study Details

Study typeRct
EvidenceLevel 2
PublishedApr 2026
View Original Abstract ↓
OBJECTIVES: Test the hypothesis that conservative fluid management with active deresuscitation would not adversely affect tissue perfusion or kidney injury and would be associated with reduced vascular injury compared with usual care. DESIGN: Secondary analysis of the Role of Active Deresuscitation After Resuscitation-2 (RADAR-2) trial. SETTING: ICUs. PATIENTS OR SUBJECTS: Critically ill patients enrolled in the RADAR-2 trial. INTERVENTIONS: Conservative fluid management with active deresuscitation vs. usual care. MEASUREMENTS AND MAIN RESULTS: Measures of tissue hypoperfusion (whole blood lactate), acute kidney injury (AKIRisk score and urinary cystatin-C), and vascular injury (plasma hyaluronan, syndecan-1, and angiopoietin-2) were compared between groups. For each analyte, change from baseline was compared between groups and the median inter-group difference at each timepoint was estimated with bootstrapped CIs. Exploratory logistic regression examined associations between plasma biomarker levels (including N-terminal pro-B-type natriuretic peptide [NT-proBNP]), 28-day mortality, and treatment allocation. Whole blood lactate levels were similar between groups at all timepoints. Using change from baseline comparisons, no statistically detectable between-group differences were observed in AKIRisk scores or urinary cystatin-C levels. Plasma vascular injury biomarkers showed no statistically detectable between-group differences at any timepoint. High baseline hyaluronan (adjusted odds ratio [aOR], 5.75; 95% CI, 1.94-17.02; p = 0.002), syndecan-1 (aOR, 8.82; 95% CI, 2.67-29.15; p < 0.001), and NT-proBNP greater than 2500 pg/mL (aOR, 21.48; 95% CI, 3.57-129.41; p < 0.001) were independently associated with increased 28-day mortality. There was no evidence of differential treatment response based on these biomarker levels. CONCLUSIONS: Conservative fluid management and active deresuscitation were not associated with worsening tissue perfusion or acute kidney injury. A reduction in vascular injury markers was not observed. Given the modest sample size and resultant imprecision, clinically important effects cannot be excluded.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.